Therapeutic Glaucoma

Glaucoma

Technology

GLAUCOMA 360

Your unrestricted view into eyecare conferences across the spectrum. Gain exclusive access to Ophthalmology Times® expert-led conference coverage from major meetings throughout the year featuring articles, videos, and insights shared by prominent experts of the ophthalmic community.

Conferences

Glaukos Corporation's COO Chris Calcaterra gives an update on the company's latest  24-month phase 2b data for its iDose TR sustained-release travoprost implant, next steps for securing FDA approval, and his outlook for 2021. 

Glaukos COO shares product updates, 2021 pipeline